an investigational cell-based immunopotentiator, 78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including ...

J Gastroenterol Hepatol. 2013;28(1):73-77. Salivary IgA cannot be recommended as an investigation for gastrointestinal disease. Not only is the relationship between changes in IgA and ...

Many vaccine companies have developed or purchased their proprietary immunopotentiator(s) that are in most cases protected by patents. These adjuvants enable the development of unique vaccines ...

TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and approved in Taiwan ...

TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and approved ...

Inflammation and Macrophage Plasticity Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain ...

TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan by Chugai ...